Compare XBP & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBP | ACXP |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.1M | 6.2M |
| IPO Year | 2021 | 2021 |
| Metric | XBP | ACXP |
|---|---|---|
| Price | $2.90 | $1.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $95.50 |
| AVG Volume (30 Days) | 15.7K | ★ 176.5K |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 183.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $872,690,000.00 | N/A |
| Revenue This Year | $2.59 | N/A |
| Revenue Next Year | $5.75 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $1.31 |
| 52 Week High | $8.55 | $8.34 |
| Indicator | XBP | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 50.37 | 44.16 |
| Support Level | $2.82 | $1.34 |
| Resistance Level | $3.09 | $1.75 |
| Average True Range (ATR) | 0.27 | 0.05 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 71.20 | 6.67 |
XBP Global Holdings Inc is a multinational technology and services company that drives intelligent workflows for organizations. Through its proprietary platforms, agentic AI-driven automation, and domain expertise across industries and the public and private sectors, the firm enables its clients to entrust their digital transformations and workflows. The segments of the company are Applied Workflow Automation and Technology. The Applied Workflow Automation segment generates maximum revenue and provides services powered by intelligent, AI-enabled workflows that generate outcomes for client's systems, while the Technology segment focuses on the sale of recurring and perpetual software licenses, software maintenance and professional services, as well as hardware solutions and maintenance.
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.